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ScienceDirectMolecules acting in the central nervous system play a critical
role in the control of both energy and glucose homeostasis. The
hypothalamus consists of a highly diverse collection of
interconnected neurons and supporting glial cells that allow
this region of the brain to sense and respond to a diverse range
of hormonal and metabolic signals. We review recent advances
in our understanding of the anatomical architecture and
molecular mechanisms within the hypothalamus and how these
facilitate the orchestration of systemic metabolic processes.
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Introduction
The brain is crucial in regulating metabolism. From
reports describing the effects of lesioning discrete ana-
tomical regions, through to studies of human monogenic
disorders and genetically engineered murine models, the
primacy of the central nervous system in controlling
energy and glucose homeostasis remains clear [1]. In
addition, on-going associations from GWAS continue to
highlight a neuronal component to body-weight regula-
tion [2].
Within the brain, a number of anatomical regions are
recognised to play a role in metabolic homeostasis [3–4].
However, the hypothalamus in particular is critical in
sensing and integrating signals from the periphery and
Open access under CC BY license. 
Current Opinion in Pharmacology 2013, 13:970–976 effecting appropriate physiological changes to maintain
homeostasis.
Here, we review emerging data on anatomical consider-
ations that make the hypothalamus so well adapted to this
role. We will also focus on studies of the leptin-melano-
cortin pathway, exploring how different physiological
functions are subserved by different hypothalamic popu-
lations. We discuss developments in our understanding of
the cross talk between the hypothalamus and peripheral
organs in the control of glucose homeostasis and highlight
data on more novel circulating metabolic signals poten-
tially acting through the hypothalamus.
Tanycytes and the blood–brain barrier
In order to access neuronal populations, circulating mol-
ecules have to negotiate past the blood–brain barrier
(BBB). The BBB is composed of tight junctions between
the endothelial cells lining brain microvasculature and
serves to regulate access of circulating factors into the
brain parenchyma. However, there are discrete regions of
the brain known as the circumventricular organs (CVO),
in which the brain endothelium is fenestrated. This
includes the median eminence (ME) of the basal hypo-
thalamus, situated ventral to the 3rd ventricle and adja-
cent to the arcuate nucleus (ARC). The ME also contains
tanycytes, a population of highly polarised glial cells that
line the 3rd ventricle and send long projections down into
the capillary network lying deeper within the ME. Inves-
tigators in Lille have previously shown that there is
regional variation in the distribution of tight junction
proteins in this area and have postulated that the ME
may acts as a privileged site for peripheral molecules to
specifically target the ARC [5–6]. Data now emerging
from this group indicate that within the ME there is a
degree of previously unappreciated plasticity in the inter-
face between brain and circulation. Using in vivo imaging
to detect fluorescently labelled ligand, Schaeffer et al.
demonstrated that circulating ghrelin (a stomach derived
orexigenic protein) rapidly bound neurons in the vicinity
of fenestrated capillaries, with the amount of ghrelin
bound to NPY neurons directly influenced by nutritional
state [7]. In particular, fasting significantly increased the
number of NPY fluorescent-ghrelin labelled neurons,
with this labelling falling away with re-feeding.
Langlet et al. reported that fasting both increased the
tight junction barrier of tanyctes lining the third ventricle
and increased fenestration of the microvasculature run-
ning from the ME into the ARC. This gliovascularwww.sciencedirect.com
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glucoprivation and was duly reversed by raising blood
glucose levels, with VEGF-A produced in tanycytes
appearing critical in modulating these barrier properties
[8].
A potential role for tanycytes in brain glucose sensing
has also been investigated by Lanfray et al. who have
identified that regulation of feeding by glucose may be
mediated through glial production of endozepines, a
family of peptides produced specifically in glial cells,
which are known to bind benzodiazepine receptors [9].
The endozapine octadecaneuropeptide (ODN) has a
potent suppressive effect upon appetite when given
centrally and, intriguingly, Lanfray and colleagues
showed that central administration of an ODN agonist
suppressed the hyperphagic response induced by
glucoprivation, whilst central administration of an
ODN antagonist suppressed the anorexigenic effect
of glucose.
Tanycytes may also have other specialised roles. Lee et al.
reported that ME tanycytes have a neurogenic capacity
with disruption of these cells by CT guided irradiation
leading to changes in body weight, energy expenditure
and activity [10]. Studies by Haan et al. have also impli-
cated hypothalamic tanycytes as a population of progeni-
tor cells, being able to populate appetite-regulating
centres such as the ARC with neurons through postnatal
life and into adulthood [11].
Leptin action within the hypothalamus
The hypothalamic arcuate nucleus contains two popu-
lations of cells that are the best characterised leptin-
responsive neurons in the brain [12]. A long-standing
working model states that leptin inhibits orexigenic
AgRP/NPY neurons and excites anorexigenic POMC
neurons, with both sets of neurons projecting further
to second-order neuronal populations, both within and
beyond the hypothalamus. However, whilst these two
neuronal populations undoubtedly play pivotal roles in
energy homeostasis, many studies over the last decade,
driven by advances in Cre-lox technology, have unsur-
prisingly revealed far more complexity to the action of
leptin within the hypothalamus, both in terms of site of
action and ascribed role [13]. Thus, compared to mice
globally lacking leptin receptors, the obesity phenotype
in mice lacking leptin receptors from POMC neurons
alone is much less pronounced [14]. Similarly, body
weight is increased by Lepr deletion from AgRP neurons,
with simultaneous deletion in both POMC and AgRP
neurons having an incremental effect on obesity [15].
The non redundant role of leptin receptors elsewhere in
the hypothalamus is highlighted by the findings that
selective deletion of Leprb in SF1 (steroidogenic factor
1) neurons of the VMH also produces modest obesity
[16].www.sciencedirect.com Hypothalamic leptin receptors may also have a role in
glucose homeostasis. db/db animals globally lacking func-
tional leptin receptors are hyperphagic, obese and have
elevated glucose and insulin levels. Several groups have
demonstrated in db/db animals that selective re-expression
of the leptin receptor in just one side of the arcuate or
within arcuate POMC neurons produces robust improve-
ments in the glucose/insulin profile, while body weight is
only modestly reduced [17–18] Similar results have been
reported by Berglund and colleagues using a model where
endogenous LEPR expression was prevented by a LoxP-
flanked transcription blocker (loxTB), but could be reac-
tivated by Cre recombinase. Re-expression of LEPR only
in POMC neurons in the ARC had only a modest effect on
energy balance with the authors arguing that the normal-
isation of blood glucose and reduction in hepatic insulin
resistance was independent of changes in body weight [19].
POMC neurons also express insulin receptors and several
recent studies have focused on dissecting the interplay of
leptin and insulin on these neurons. Williams et al. have
indicated that leptin-induced c-fos activity within ARC
POMC neurons defines a separate population from
POMC neurons that express insulin receptors, with the
acute responses to leptin and insulin largely segregated in
distinct subpopulations of POMC cells [20]. Intriguingly
Hill et al. showed that mice lacking both leptin and insulin
receptors in POMC neurons display systemic insulin
resistance, which is distinct from the single deletion of
either receptor, indicating that direct action of both
insulin and leptin on POMC neurons may be required
to maintain normal glucose homeostasis [21].
Serotonin signalling within the hypothalamus
and the control of appetite
The effects of serotonin (5-hydroxytryptamine, 5-HT) on
physiology are mediated by multiple serotonin receptors (5-
HTRs). The last five years have seen an increased un-
derstanding in the role of the 5-hydroxytryptamine 2C
receptors (5-HT2CRs) within the hypothalamus and how
they can influence melanocortin tone. Xu et al. generated
mice with global 5-HT2CR deficiency and mice with 5-
HT2CRs re-expressed only on POMC neurons [22]. The
global null mice developed hyperphagia and obesity, but
both were normalised with selective re-expression on
POMC neurons only. 5-HT(2C)Rs expressing POMC
neurons have also been implicated as being relevant reg-
ulators of insulin sensitivity and hepatic glucose homeosta-
sis independent, at least in part, of their role in appetitive
behaviour [23]. More mechanistic data on how this receptor
functions has recently been uncovered, with the putative
transient receptor potential C (TRPC) channels reported to
mediate the activation of a subpopulation of POMC
neurons by mCPP (a 5-HT(2C)R agonist) [24].
This increase in functional knowledge has driven a
renewed interest in the development of pharmacologicalCurrent Opinion in Pharmacology 2013, 13:970–976
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long been known to reduce food intake. For example,
Doslikova and colleagues have combined pharmacologi-
cal studies with electrophysiological analysis to uncover a
functional heterogeneity of ARC POMC neurons. They
defined distinct subpopulations of POMC cells activated
by 5-HT2CRs but disinhibited through a 5-HT1BR-
mediated suppression of local inhibitory inputs, thereby
suggesting that a combination of a 5-HT2CR agonist with
a 5-HT1BR agonist may be a powerful therapeutic
strategy to treat obesity [25].
Other groups have explored the possibility of a direct link
between the serotonin and leptin signalling pathways. In
2009, Yadav et al. reported that inactivation of the leptin
receptor in serotonergic neurons was able to fully reca-
pitulate the phenotype seen in db/db mice, implicating a
serotonin-dependent mechanism in the leptin regulation
of bone mass, appetite and energy expenditure [26].
However, others have questioned the validity of these
findings. Lam et al. for example, showed that although
some leptin receptor (LepRb) neurons do lie close to 5-
HT neurons in the dorsal raphe (DR), 5-HT neurons do
not co-express LepRb, making it less likely that leptin
directly influence 5-HT neurons [27].
Cellular mechanisms within POMC neurons
A number of cellular mechanisms have been identified
that, when disrupted, can interfere with POMC neuronal
function. For example, hypoxia-inducible factor (HIF), a
nuclear transcription factor that responds to environmen-
tal and pathological hypoxia, was found to directly control
the transcription of the POMC gene, with disruption of
HIF in POMC neurons impairing hypothalamic glucose
sensing and causing energy imbalance to promote obesity
development [28]. Two studies have recently implicated
autophagy, an important intracellular mechanism for the
degradation of damaged proteins and organelles, as
critical to the correct functioning of a POMC neuron.
One study showed that selective loss of autophagy in
POMC neurons decreases a-melanocyte-stimulating hor-
mone (MSH) levels, promoting adiposity, impairing lipo-
lysis and altering glucose homeostasis [29]. The second
study deleted Atg7, an important autophagy gene, in
POMC neurons, and found this disrupted the maturation
of POMC-containing axonal projections, thereby causing
higher post-weaning body weight, increased adiposity
and glucose intolerance [30]. Both studies implicated
hypothalamic autophagy deficiency in the pathogenesis
of obesity.
Hypothalamic melanocortin receptors
A number of recent reports have revealed ever more
complexity within central melanocortin receptors. Mela-
nocortin Receptor Accessory Protein 2 (MRAP2) is
a small, single-pass transmembrane protein that has
previously been shown to interact with melanocortinCurrent Opinion in Pharmacology 2013, 13:970–976 receptors in vivo [31]. Although it was recognised to be
highly expressed within hypothalamic regions enriched
with MC4R, its role in vivo was unclear. Now two con-
temporaneous reports — one based around murine
models, another using genetically modified zebrafish —
have indicated that MRAP2 may play a critical role in
modulating melanocortin tone within the hypothalamus.
Asai et al. reported that loss of Mrap2 in mice, either
globally or only within the brain, resulted in the devel-
opment of severe obesity at a young age [32]. Although it
remains to be determined whether this was driven by an
increase in food intake and/or a decrease in energy
expenditure, it appears, in part at least, to be due to a
reduction in melanocortin 4 receptor activity. Asai and
colleagues also uncovered potentially pathogenic MRAP2
genetic variants in a cohort of obese humans, suggesting
the gene may also contribute to body-weight regulation in
humans. Sebag et al. studied zebrafish to highlight an
intriguing role for MRAP in growth and development
[33]. They reported that this protein exists in two differ-
ent paralogs, MRAP2a and MRAP2 b. Expressed in the
larval, MRAP2a blocked the function of MC4R, thus
stimulating growth during larval development. In contrast
MRAP2b was expressed later in development, appearing
to enhance responsiveness to a-MSH once the zebrafish
began feeding and thereby adding another regulatory step
in the feeding pathway.
Thus far, the MC3R has remained the ‘lesser sibling’ of
the two central melanocortin receptors, at least with
respect to their role in the control of food intake. How-
ever, Renquist and colleagues have reported that the
Mc3r/ mouse exhibits defective fasting-induced
refeeding, white adipose tissue lipolysis, liver triglyceride
accumulation, and regulation of the adipostatic and hypo-
thalamic-adrenal-pituitary axes [34]. These data indicate
that MC3R may be required for communicating nutri-
tional status to both central and peripheral tissues
involved in nutrient partitioning.
Finally, the role of melanocortin 4 receptor signalling in
the response to two different variations of bariatric
surgery has recently been studied. Bariatric surgical pro-
cedures such as Roux-en-Y gastric bypass (RYGB) and
Vertical Sleeve Gastrectomy (VSG) are effective long-
term therapy for the treatment of severe obesity. Such
procedures likely bring about weight loss through
multiple physiological mechanisms, involving changes
in food intake, food preference and energy expenditure.
Hatoum et al. reported that while Mc4r+/ mice remained
fully responsive to RYGB, Mc4r/ mice lost substan-
tially less weight after surgery than wild-type animals,
indicating that MC4R signalling is necessary for the
weight loss effects of RYGB [35]. In contrast, Mul and
colleagues reported that both Mc4r+/ and Mc4r/ rats
were fully responsive to VSG [36]. The reasons under-
lying the differences between these two studies are notwww.sciencedirect.com
Hypothalamic control of metabolism Coll and Yeo 973clear, but it may be that different surgical procedures, as
well as species differences between mice and rats, all
contribute to influence the interactions between geno-
type and bariatric surgery outcome.
Cross talk between the hypothalamus and
peripheral organs controlling glucose
homeostasis
Glucose
Subgroups of ‘glucose sensing’ neurons within the lateral,
arcuate, and ventromedial hypothalamic regions are well
recognised to display specific excitatory or inhibitory
electrical responses to changes in extracellular glucose
levels [37].
Glucose sensing on POMC neurons has been reported to
have a role in the physiological control of systemic blood
glucose [38]. Parton et al. disrupted ATP-sensitive pot-
assium (K(ATP)) channels in glucose excited POMC
neurons and found that whole-body response to a
systemic glucose challenge was significantly impaired.
This group also reported that an alteration of UCP2-
mediated glucose sensing in these same neurons could
be demonstrated in obese mice on a high-fat diet,
suggesting that loss of glucose sensing by POMC neurons
may have a role in the development of type 2 diabetes.
Osundiji et al. provided evidence that hypothalamic glu-
cose sensors may play a role in controlling insulin
secretion from the pancreas. As well as reporting that
activation of hypothalamic glucose sensing neurons by
ICV infusion of glucose improves insulin secretion during
a glucose tolerance test, they demonstrated that pharma-
cological inhibition of hypothalamic glucose sensing sig-
nificantly impaired first-phase insulin secretion following
an intravenous glucose bolus [39].
Insulin
Insulin receptors are widely distributed in the brain and
are highly expressed within the ARC. Chronic ICV infu-
sion of insulin can reduce food intake [40], neuron-
specific loss of insulin receptors throughout the brain
brings about a modest increase in body fat [41], and
specific loss of insulin receptors within hypothalamic
nuclei adjacent to the 3rd ventricle causes hyperphagia
[42]. Despite these data, the physiological relevance and
role of hypothalamic insulin sensing remains to be fully
determined. One particularly contentious area relates to
the role of CNS insulin signalling in the regulation of
hepatic glucose metabolism. Multiple studies based in
rodent models suggest that central insulin signalling
modifies neural output to the liver and is required for
the rapid suppression of hepatic glucose production [43].
However, work done by Cherrington and others
(reviewed in [44]) makes a compelling case that
although the brains of larger animals can sense changeswww.sciencedirect.com in plasma insulin levels and effect hepatic gene transcrip-
tion, in terms of changes in hepatic glucose flux, this
central effect is subsumed under/by the more dominant
direct hepatic effect of insulin. For example, in a study in
conscious dogs in which an acute physiological rise in
insulin was brought about by hepatic portal vein insulin,
Ramnanan et al. reported that concomitant inhibition of
hypothalamic insulin action did not alter the effects of the
hormone on hepatic glucose flux [45].
It may be that this central insulin signalling has more of a
role in the longer term, setting a basal tone for hepatic
glucose metabolism, with chronic hypothalamic insulin
resistance contributing, at least in part, to hepatic insulin
resistance. Other data do speak to a putative link between
the hypothalamus and hepatic glucose metabolism. For
example, Coomans et al. studied the metabolism of mice
that had undergone bilateral supra-chiasmatic lesioning,
and argued that damage to a discrete hypothalamic region
engenders a magnitude of insulin resistance in the liver
far in excess of that expected with the modest concomi-
tant weight gain [46]. It may also be that signals other than
glucose and insulin are involved. Su et al. have recently
suggested the elevation in circulating levels of leucine
postprandially are sensed by the brain through the metab-
olism of leucine to acetyl-CoA and malonyl-CoA in the
mediobasal hypothalamus, and thereby able to lower
plasma glucose levels through inhibition of liver glucose
output.
Thyroid action in the hypothalamus
Thyroid hormones can also influence feeding behaviour.
Tri-iodothyronine (T3) is able to increase food intake by
acting within the brain [47], but as this hormone has
cellular effects on many other tissues, the degree to which
these CNS actions contribute to global energy balance
has often been contentious. However, Lo´pez and col-
leagues have confirmed the effect of thyroid hormones
within the hypothalamus to be critical in mediating their
physiological and pathophysiological effects on energy
balance [48]. Combining stereotactic delivery of hor-
mones, pharmacological agents and adenoviral vectors to
discrete regions of the hypothalamus, together with
detailed whole-body metabolic phenotyping, their results
demonstrated that thyroid-hormone-induced modulation
of AMPK activity and lipid metabolism in the hypothala-
mus is an important regulator of energy homeostasis. T3
induced a hyperphagic response driven by changes in the
levels of orexigenic and anorexigenic hypothalamic
neuropeptides, as well as marked upregulation of de novo
lipogenesis specifically in the hypothalamus and acti-
vation of BAT via the sympathetic nervous system.
More recently, the same group have extended their
analysis of hypothalamic thyroid action and implicated
mammalian target of rapamycin (mTOR) signalling as
having a role in thyroid induced feeding behaviour [49].Current Opinion in Pharmacology 2013, 13:970–976
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tion of the hypothalamic mammalian target of rapamycin
(mTOR) signalling pathway. Further, both central
administration of T3 and genetic activation of thyroid
hormone signalling in the ARC recapitulated the effects
of hyperthyroidism effects upon feeding and the mTOR
pathway. Finally, central inhibition of mTOR signalling
with rapamycin was effective in reducing the hyperpha-
gia.
Amino acid sensing in the hypothalamus
Two recent studies have provided more detail as to how
the sensing of amino acids in the hypothalamus may
influence orexigenic and anorexigenic pathways control-
ling energy balance. Karnani et al. showed that orexin/
hypocretin neurons are activated by dietary amino acids
(AAs), through a dual mechanism involving inhibition of
KATP channels and activation of system-A amino acid
transporters, implying that orx/hcrt cells sense macronu-
trient balance in extracellular fluid [50]. In another study,
our group has described a role for FTO (Fat mass and
Obesity Associated), a gene strongly associated with
human obesity, in the coupling of amino acid levels to
mammalian Target Of Rapamycin Complex 1
(mTORC1) signalling, suggesting that FTO may influ-
ence body composition through playing a role in cellular
nutrient sensing [51].
Fibroblast growth factors and potential
central actions
FGF21
Fibroblast growth factor-21 (FGF21) is a peptide hor-
mone secreted by the liver and other tissues that is
increasingly recognised to be a key physiological regu-
lator of the adaptive starvation response [52]. Amongst
the many metabolic effects ascribed to it, FGF21 induces
hepatic fatty acid oxidation and ketogenesis, increases
insulin sensitivity and inhibits somatic growth [52]. Cir-
culating FGF21 can enter the brain and some of its
diverse effects may, in part, be mediated centrally [53].
Sarruf et al. infused recombinant human FGF21 into the
lateral ventricles of obese rats at a dose that did not appear
to cross back into the peripheral circulation. This inter-
vention increased both food intake and energy expendi-
ture but had no effect on total body weight or fat content.
Despite this, there was a significant improvement of
insulin sensitivity by increased insulin-mediated suppres-
sion of endogenous glucose production. However, a full
understanding of the site and receptor through which
these actions are mediated remains to be determined.
FGF19
Fibroblast growth factor-19 (FGF19) is a hormone
produced in the distal ileum and secreted into the circu-
lation after a meal. While it is recognised to control the
enterohepatic circulation of bile acids, FGF15/19 also
regulates hepatic protein and glycogen metabolism inCurrent Opinion in Pharmacology 2013, 13:970–976 an insulin-independent manner [54]. Recent data have
emerged to indicate that, like many other gut derived
hormones, FGF19 may also have an effect upon metab-
olism via the central nervous system [55]. Ryan et al.
reported that not only are FGF-receptors 1 and 4 present
in the rodent hypothalamus, but also that high fat feeding
significantly reduced their expression levels. ICV admin-
istration of FGF19 reduced food intake and body weigh
while similar administration of an FGF-receptor inhibitor
increased food intake and impaired glucose tolerance.
Conclusions
The importance of the role of the hypothalamus in
controlling metabolism remains undiminished. During
a time when many investigators have, quite appropriately,
moved away from a purely ‘hypothalamo-centric’ view of
the pathways governing energy homeostasis to concen-
trate on the brainstem, cortex and reward centres, so our
understanding of the intrinsic apparatus of the hypothala-
mus has increased. Perhaps not surprisingly, there
remains a high degree of intricacy, both within and
between neuronal populations. However, as the design
of successful management strategies for the treatment of
metabolic disorders is dependent upon a better under-
standing of the fundamental mechanisms of appetite and
energy balance, there remains an imperative to continue
to explore these systems. The major pathways within the
brain that control food intake are highly conserved
amongst mammals, with naturally occurring or genetically
modified, murine models closely matching the phenotype
of many of the human monogenic obesity disorders. As an
increasing number of novel genetic loci continue to be
identified, model organisms will continue to play a major
role in unravelling the complex and intricate circuitry
involved.
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